SCHEDULE: David Lazar Exits Cyclacel Pharmaceuticals Stake
Beneficial Ownership Change
David E. Lazar has fully divested his beneficial ownership in Cyclacel Pharmaceuticals, Inc., reducing his stake to 0%.
Summary
- David E. Lazar filed Amendment No. 2 to his Schedule 13D, indicating a complete divestment of his beneficial ownership in Cyclacel Pharmaceuticals, Inc.
- As of the close of business on August 5, 2025, Lazar no longer beneficially owns any shares of the company's common stock, resulting in a 0% ownership stake.
- This Amendment No. 2 serves as the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.
- The aggregate percentage of shares owned by the Reporting Person is based upon 1,583,965 shares of Common Stock outstanding as of July 10, 2025, as reported in the Issuer's Registration Statement on Form S-1 filed on July 30, 2025.
- Transactions within the past sixty days include the sale of 15,011 shares at $9.65 per share on August 4, 2025, and 114,618 shares at $9.31 per share on August 5, 2025.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of a shareholder's complete divestment of shares and does not contain information that would inherently indicate positive or negative sentiment for the company's operations or financial health.
Future Outlook
No future outlook or guidance for Cyclacel Pharmaceuticals, Inc. is provided in this filing, as it pertains solely to a change in beneficial ownership by an individual.
Industry Context
This filing is a standard disclosure of a change in beneficial ownership by an individual investor and does not inherently relate to broader industry trends or competitors, beyond the general market activity of share sales.
Stakeholder Impact
- The complete divestment by a beneficial owner could lead to minor shifts in the shareholder base. However, without knowing the size of the previous stake relative to total shares or the nature of the investor, the direct impact on other stakeholders (employees, customers, suppliers, creditors) is likely minimal.
Next Steps
- The filing states it is a 'final amendment' and 'constitutes an exit filing' for the Reporting Person, implying no further actions are expected from this specific reporting person regarding this stake.
Key Dates
| Date | Description |
|---|---|
| 2025-07-10 | Date shares outstanding (1,583,965) were reported in Issuer's Form S-1. |
| 2025-07-30 | Date Issuer's Registration Statement on Form S-1 was filed with the Securities and Exchange Commission. |
| 2025-08-04 | Date of sale for 15,011 shares at $9.65 per share. |
| 2025-08-05 | Date of event requiring filing, when Reporting Person no longer beneficially owned any shares; also date of sale for 114,618 shares at $9.31 per share. |
| 2025-08-08 | Date the Schedule 13D Amendment No. 2 was signed. |
Keywords
Cyclacel Pharmaceuticals, David E. Lazar, Schedule 13D, Beneficial Ownership, Share Sale, Divestment, Exit Filing, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.